DOCSLIB.ORG

Hydrochlorothiazide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hydrochlorothiazide HYDROCHLOROTHIAZIDE 1. Exposure Data 1.1.2 Structural and molecular formulae and relative molecular mass 1.1 Identification of the agent O O OO 1.1.1 Nomenclature S S N H Chem. Abstr. Serv. Reg. No.: 58-93-5 (SciFinder, H2N 2013) Cl N Chem. Abstr. Serv. Name: 2H-1,2,4-Benzo- H thiadiazine-7-sulfonamide, 6-chloro-3,4-di- hydro-1,1-dioxide (SciFinder, 2013) IUPAC systematic name: 6-Chloro-1,1-dioxo- C7H8ClN3O4S2 3,4-dihydro-2H-1,2,4-benzothiadiazine-7- Relative molecular mass: 297.74 (O’Neil, 2001) sulfonamide Synonyms: Dihydrochlorothiazid; Dihydro- 1.1.3 Chemical and physical properties of the chloro thiazide; Dihydrochlorothiazidum; pure substance Di hy dro chlorurit; Dihydrochlorurite; Di hy dro xychlorothiazidum; HCTZ; HCZ; Description: A white or almost white, crys- Hydrochlorothiazid; Hydrochlorthiazide talline powder; odourless or almost odourless (DrugBank, 2013); Hidroclorotiazida; (WHO, 2006) Hydrochlorothiazidum; Chlorsulfonamido- Density: 1.693 g/cm3 (calculated) (Lookchem, dihydrobenzothiadiazine dioxide; Chloro- 2013) sulthiadil; 3,4-dihydrochloro thiazide (IPCS, 2013) Melting point: 273–275 °C (O’Neil, 2001) WHO International Nonproprietary Name Spectroscopy data: Infrared, Raman, ultra- (INN): Hydrochlorothiazidum (WHO, 2006) violet, proton nuclear magnetic resonance (1H-NMR) and 13C-NMR spectral data have been reported. Solubility: Very slightly soluble in water (722 mg/L at 25 °C; Deppeler, 1981); soluble in ethanol at ~750 g/L and in acetone (WHO, 2006); soluble in dilute ammonia; freely soluble in sodium hydroxide solution, in 285 IARC MONOGRAPHS – 108 n-butylamine and in dimethylformamide; • 6-Chloro-N-[(6-chloro-7-sulfamoyl-2,3- sparingly soluble in alcohol; insoluble in dihy dro-4H-1,2,4-benzothiadiazin-4-yl ether, chloroform and in dilute mineral acids 1,1-dioxide)methyl]-3,4-dihydro-2H- (HSDB, 2013). 1,2,4-benzothiadiazine-7-sulfonamide Octanol/water partition coefficient (log P): 1,1-dioxide. −0.07 (Chemspider, 2013) Dissociation constant: pK = 7.9 ; pK = 9.2 a a2 1.2 Analysis (O’Neil, 2001) An overview of selected analytical methods is 1.1.4 Technical products and impurities presented in Table 1.1. (a) Trade names 1.3 Production and use Acuren; Adelphan; Apo-Hydro; Aqua- zide; Clorana; Colidur; Colonraitai; Cotrazid; 1.3.1 Production process Decazon; Dehydratin; Dehydrazid; Depress; Hydrochlorothiazide is synthesized by Dichlotride; Dichlozid; Di-Eudrin; Dihydrochl either the reaction of para-formaldehyde with Ozide; Dihydrochlorothiazide; Dihydrodiazid; 5-chloro-2,4-disulfamoylaniline in nonaqueous Disalunil; Disothiazide; Dithiazide; Dithiazide; media, or the reaction of formaldehyde with Diunorm; Diunorm; Diurace; Diural; Diuren; 6-chloro-7-sulfamoyl-2H-1,2,4-benzothiadi- Diurex; Diurezin; Diuzid; Do-Hydro; Drenol; azine-1,1-dioxide in aqueous alkaline solution Duberzide; Edepress; Esidrex; Esidrix; H.C.T.; (Deppeler, 1981). HCT [manufacturer]; Hexazide; Hidro- clorotiazida; Hidrochlorotiazid Alkaloid; 1.3.2 Use Hidro med; Hidroronol; Hidrosaluretil; Hidro- tiadol; HTZ; Hybozide; Hychlozide; Hydrex; (a) Indications Hydride; Hydrochlorothiazide; Hydrochloro- Hydrochlorothiazide is a thiazide-type thiazidum Polpharma; Hydroklortiazid diuretic chiefly used as an antihypertension Evo lan; Hydromed; Hydrozide; Hypodehydra; agent for the control of elevated blood pres- Hypothiazid; Hytaz; Hyzide; Keshiau; Klorzide; sure (Table 1.2). It is often combined with other Koliside; Locoid; Lonpra; Microzide; Monozid; agents in the treatment of hypertension, either Nefrix; Newtolide; Nisidrex; Nor-Tiazida; Oretic; through separate prescriptions for hydrochloro- Ridaq; Rofucal; Tandiur; Tiazid; Urilzid; Xenia thiazide and the other agents, or through the use (MicroMedex, 2013). of combination products in which a single tablet (b) Impurities contains hydrochlorothiazide plus one other antihypertensive medication (more rarely, two Some impurities are described in the other agents). European Pharmacopoeia (2005): In the USA, hydrochlorothiazide is indicated • Chlorothiazide (active drug rarely used as an for “the management of hypertension either as alternative to hydrochlorothiazide) the sole therapeutic agent or in combination • 4-Amino-6-chlorobenzene-1,3-disulfona- with other antihypertensives” and is recom- mide (salamide) mended as first-line medication Chobanian( et al., 2003). The Food and Drug Administration 286 Table 1.1 Analytical methods for hydrochlorothiazide Sample matrix Sample preparation Analytical method Detection limit Reference Compendial methods Assay – Potentiometry – Indian Titrant: 0.1 M TBAH Pharmacopoeia Reference electrode: calomel or silver–silver chloride (2010) Indicator electrode: glass electrode 1 mL of 0.1 M TBAH is equivalent to 0.01488 g of HCTZ Assay for – UV-visible spectroscopy wavelength: 273 nm – Indian HCTZ tablets Pharmacopoeia (2010) Assay for – HPLC column: C18 – US HCTZ tablets Mobile phase: monobasic sodium phosphate and acetonitrile Pharmacopeia (9 : 1) (2007) pH 3.0 ± 0.1 Flow rate: 2 mL/min Non-compendial methods Human plasma Addition of internal standard (clortalidone) HPLC–tandem mass spectrometry 5 ng/mL (LLOQ) Sousa et al. and MTBE, centrifugation, addition of Column: C18 Linearity: (2009) solvent to organic phase, evaporation and Mobile phase: acetonitrile and water (80 : 20, v/v) SRM 5–400 ng/mL reconstitution in acetonitrile and water transition: 296.10 m/z, 204.85 m/z (1 : 1, v/v) Human urine Mix urine samples with deionized water, HPLC–narrow bore chromatography 1 µg/mL (LOD) Farthing et al. centrifuge Column: C18 Linearity: (1998) Mobile phase: acetic acid and acetonitrile (93 : 7) pH 3 2–50 µg/mL Wavelength: 272 nm Flow rate: 0.30 mL/min Human serum Gel filtration of the sera on Sephadex G-15, HPLC 50 ng/mL (LOD) Christophersen extraction of the protein-free fraction of the Column: C18 (Spherisorb ODS) et al. (1977) effluent with ethyl acetate Mobile phase: 15% methanol in water Rat plasma To plasma add internal standard (HFTZ), LC–ESI–MS Linearity: Takubo et al. Hydrochlorothiazide extraction with MTBE Column: C8 4–1000 ng/mL (2004) Mobile phase: distilled water and acetonitrile (85 : 15) Accuracy: Negative ionization mode 100.8–113.1% Precision: 0.28–16.4% 287 288 IARC MONOGRAPHSIARC 108 – Table 1.1 (continued) Sample matrix Sample preparation Analytical method Detection limit Reference Human plasma, Derivatization with Reverse phase HPLC 3.3 ng/mL Huang et al. simultaneous 2,4-dibromoacetophenone (pBPB) to form Column: C18 (LOQ) (2006) determination captopril-pBPB adduct. Extraction of Mobile phase: acetonitrile, trifluoroacetic acid and water of HCTZ and HCTZ and derivatized captopril with ether (gradient elution) captopril and dichloromethane Flow rate:1.2 mL/min Human plasma, Liquid–liquid extraction with diethyl ether LC–MS Linearity: Yan et al. simultaneous and dichloromethane (60 : 40) Column: C8 1.00–600 ng/mL (2008) quantitation Mobile phase: acetonitrile, 10 mM ammonium acetate and of HCTZ and formic acid (gradient elution) telmisartan Flow rate: 1.2 mL/min SRM transition: 295.9 m/z → 268.9 m/z Negative ionization mode Human blood Addition of the internal standard, benzene GLC 0.05 µg/mL Vandenheuvel and plasma extraction, extraction with ethyl acetate, Column: glass U-tube (sensitivity) et al. (1975) back-extraction into NH4OH, adjustment Carrier gas: argon : methane (95 : 5) to pH 3.7 and extraction with ethyl acetate, Flow rate: 60 mL/min evaporation, dissolution of the residue in Detector: electron capture detector trimethylanilinium hydroxide in methanol In tablets Dissolve drug in 0.02 M NaOH, dilute with Electrochemical study 5.0 ng/mL Abdel Razak Britton–Robinson buffer pH 3.3 Electrode: glass carbon electrode (LOD) (2004) pH 3.3 Oxidation potential: + 1040 mV In urine Centrifugation at 4000 g/mL spiked with Electrochemical study 14 ng/mL Abdel Razak HCTZ and diluted with Britton–Robinson Electrode: glass carbon electrode (2004) buffer pH 3.3 pH 3.3 Oxidation potential: + 1040 mV In Solution of HCTZ in acetone Diffuse reflectance spectroscopy: Whatman 42 filter paper as 1.32 × 10−2 mol/L Gotardo et al. pharmaceutical the solid support (LOD) (2005) formulations Solvents: acetone and methanol (HPLC grade); PDAC used Linearity: for spot reaction with HCTZ 3.36 × 10−2 to 1.01 × 10−1 mol/L GLC, gas-liquid chromatography; HCTZ, hydrochlorothiazide; HFTZ, hydrofluorothiazide; HPLC, high-performance liquid chromatography; LC-MS, liquid chromatography mass spectroscopy; LC–ESI–MS, liquid chromatography–electrospray ionization–mass spectrometry; LOD, limit of detection; LLOQ, lower limit of quantification; LOQ, limit of quantification; MTBE, methyl tert-butyl ether; PDAC, para-dimethylamino cinnamaldehyde; SRM, single reaction monitoring; TBAH, tetrabutylammoniumhydroxide; UV, ultraviolet; v/v, volume per volume Hydrochlorothiazide Table 1.2 Most commonly reported clinical indications for hydrochlorothiazide in the USA, 2012 Diagnosisa ICD-9 code Drug uses (in thousands) Percentage of total Essential hypertension, NOS 401.90 21 194 86.9 Hypertensive heart disease, other 402.90 713 2.9 Chronic ischaemic disease, unspecified, with hypertension 414.50 324 1.3 Hypertension, benign 401.10 187 0.8 Surgery after heart disease V67.03 153 0.6 Hypertensive renal disease 403.90 136 0.6 Oedema, NOS 782.30 122 0.5 Cerebrovascular accident 436.00 86 0.4 Metabolic/insulin resistance syndrome 277.70 82 0.3 All other diagnoses – 1 332 5.5 Total with reported diagnoses – 24 383 100 a No diagnosis was stated for 0.2% of drug uses. NOS, not otherwise specified
Load more

Recommended publications
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Still an Important Cause of Heart Failure?
    Journal of Human Hypertension (2005) 19, 267–275 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh REVIEW ARTICLE Hypertension — still an important cause of heart failure? E Kazzam1, BA Ghurbana2, EN Obineche1 and MG Nicholls1 1Department of Internal Medicine, Faculty of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; 2Department of Medicine, Al Ain Hospital, Al Ain, United Arab Emirates Hypertension has been the single most important risk from highly selected study groups in tertiary referral factor for heart failure until the last few decades. Now, it centres to patients with heart failure in primary and is frequently claimed that atherosclerotic coronary secondary care, may not be justified. Finally, the artery disease dominates as the major underlying cause, situation of heart failure primarily due to impaired left and hypertension is of lesser importance. We here ventricular diastolic function, where hypertension is a review evidence regarding the contribution of hyperten- frequent precursor, is often ignored in discussions of sion to heart failure in the recent decades. It is not aetiology. Our view is that hypertension remains and possible, in our view, to be confident of the relative probably is the single most, important modifiable risk importance of hypertension and coronary artery disease factor for cardiac failure in some races and countries, since there are significant limitations in the available where the dominant cardiac abnormality is left ventri- data. The often-questionable diagnostic criteria used in cular diastolic dysfunction. The situation is less clear for defining heart failure is one such limitation.
    [Show full text]
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 10, October 1995 DIURETICS IN CHILDREN • Overview • Loop Diuretics • Thiazide Diuretics • Metolazone • Potassium Sparing Diuretics • Diuretic Dosages • Efficacy of Diuretics in Chronic Pulmonary Disease • Summary • References Pharmacology Literature Reviews • Ibuprofen Overdosage • Predicting Creatinine Clearance Formulary Update Diuretics are used for a wide variety of conditions in infancy and childhood, including the management of pulmonary diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD)(1 -5). Both RDS and BPD are often associated with underlying pulmonary edema and clinical improvement has been documented with diuretic use.6 Diuretics also play a major role in the management of congestive heart failure (CHF), which is frequently the result of congenital heart disease (7). Other indications, include hypertension due to the presence of cardiac or renal dysfunction. Hypertension in children is often resistant to therapy, requiring the use of multidrug regimens for optimal blood pressure control (8). Control of fluid and electrolyte status in the pediatric population remains a therapeutic challenge due to the profound effects of age and development on renal function. Although diuretics have been used extensively in infants and children, few controlled studies have been conducted to define the pharmacokinetics and pharmacodynamics of diuretics in this population. Nonetheless, diuretic therapy has become an important part of the management of critically ill infants and children. This issue will review the mechanisms of action, monitoring parameters, and indications for use of diuretics in the pediatric population (1-5). Loop Diuretics Loop diuretics are the most potent of the available diuretics (4).
    [Show full text]
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972
    Eye (2011) 25, 971–980 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye 1,2 1 1 Non-steroidal drug- MR Razeghinejad , MJ Pro and LJ Katz REVIEW induced glaucoma Abstract vision. The majority of drugs listed as contraindicated in glaucoma are concerned with Numerous systemically used drugs are CAG. These medications may incite an attack in involved in drug-induced glaucoma. Most those individuals with narrow iridocorneal reported cases of non-steroidal drug-induced angle.3 At least one-third of acute closed-angle glaucoma are closed-angle glaucoma (CAG). glaucoma (ACAG) cases are related to an Indeed, many routinely used drugs that have over-the-counter or prescription drug.1 Prevalence sympathomimetic or parasympatholytic of narrow angles in whites from the Framingham properties can cause pupillary block CAG in study was 3.8%. Narrow angles are more individuals with narrow iridocorneal angle. The resulting acute glaucoma occurs much common in the Asian population. A study of a more commonly unilaterally and only rarely Vietnamese population estimated a prevalence 4 bilaterally. CAG secondary to sulfa drugs is a of occludable angles at 8.5%. The reported bilateral non-pupillary block type and is due prevalence of elevated IOP months to years to forward movement of iris–lens diaphragm, after controlling ACAG with laser iridotomy 5,6 which occurs in individuals with narrow or ranges from 24 to 72%. Additionally, a open iridocorneal angle. A few agents, significant decrease in retinal nerve fiber layer including antineoplastics, may induce thickness and an increase in the cup/disc ratio open-angle glaucoma.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Journal of Pharmaceutical and Biomedical Analysis Stability Of
    Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 519–524 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis journal homepage: www.elsevier.com/locate/jpba Short communication Stability of selected chlorinated thiazide diuretics K. Deventer a,∗, G. Baele b, P. Van Eenoo a, O.J. Pozo a, F.T. Delbeke a a DoCoLab, UGent, Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30, B-9052 Zwijnaarde, Belgium b Department of Applied Mathematics and Computer Science, Krijgslaan 281, S9, B-9000 Gent, Belgium article info abstract Article history: In sports, diuretics are used for two main reasons: to flush previously taken prohibited substances with Received 6 August 2008 forced diuresis and in sports where weight classes are involved to achieve acute weight loss. A com- Received in revised form 5 November 2008 mon property observed for thiazides is hydrolysis in aqueous media resulting in the formation of the Accepted 6 November 2008 degradation product aminobenzenedisulphonamide. This degradation product can be observed for sev- Available online 13 November 2008 eral thiazides. Because there is limited information regarding the effect of pH, temperature and light on the stability of thiazides, these parameters were investigated for chlorothiaizide, hydrochlorothiazide Keywords: and altizide. For all three compounds the degradation product could be detected after incubation at pH Doping ◦ Urine 9.5 for 48 h at 60 C. At lower pH and temperature the degradation product could not be detected for all Diuretics compounds. When samples were exposed to UV-light altizide and hydrochlorothiazide were photode- Thiazides graded to chlorothiazide. When the degradation rate between the different compounds was compared Sports for a given temperature and pH, altizide is the most unstable compound.
    [Show full text]
  • Southwest Journal of Pulmonary and Critical Care/2017/Volume 15 100 September 2017 Critical Care Case of the Month James T. Dean
    September 2017 Critical Care Case of the Month James T. Dean III, MD Tyler R. Shackelford, DO Michel Boivin, MD Division of Pulmonary, Critical Care and Sleep Medicine University of New Mexico School of Medicine Albuquerque, NM USA A 73-year-old man presented with a three-day history of diffuse abdominal pain, decreased urine output, nausea and vomiting. His past medical history included diabetes, coronary artery disease, hypertension and chronic back pain. The patient reported being started on hydrochlorothiazide, furosemide, pregabalin and diclofenac within the last week in addition to his long-standing metformin prescription. Initial vitals were significant for tachypnea, tachycardia to 120 bpm, hypothermia to 35ºC and hypotension with a blood pressure of 70/40 mm Hg. Physical exam was remarkable for bilateral lung wheezing and significant respiratory distress. Laboratory examination was concerning for a pH of 6.85, pCO2 of < 5mmHg, serum lactate of 27mmol/l, WBC of 15.6 x106 cells/cc and a serum creatinine of 8.36 mg/dl. A chest X-ray showed evidence of mild pulmonary edema and a CT of the abdomen did not show any acute pathology. What is the most likely etiology of the patient’s severe acidosis? 1. Diabetic ketoacidosis 2. Ethylene glycol poisoning 3. Metformin-associated lactic acidosis 4. Septic shock Southwest Journal of Pulmonary and Critical Care/2017/Volume 15 100 Correct! 3. Metformin-associated lactic acidosis The most likely cause of the acidosis in this situation is metformin-induced lactic acidosis (1). The patient was intubated for respiratory failure secondary to severe non- compensated metabolic acidosis and shortly thereafter was started on maximal pressor support with norepinephrine, vasopressin, epinephrine and phenylephrine.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Rational Use of Beta Blockers in Management of Hypertension Khawaja Tahir Mehmood, Fatima Amin, Hafiza Kiran Ismail, Ayesha Irfan
    Khawaja Tahir Mahmood et al /J. Pharm. Sci. & Res. Vol.3(1), 2011,1029-1034 Rational Use of Beta Blockers in Management of Hypertension Khawaja Tahir Mehmood, Fatima Amin, Hafiza Kiran Ismail, Ayesha Irfan. Lahore College for women university Lahore, Pakistan Abstract: Hypertension is an extremely common disorder. It is major risk factor for cardiovascular morbidity and mortality through its effects on target organs like brain heart kidney eyes. In Pakistan magnitude of problem of uncontrolled hypertension is greater. .Treatment of hypertension decreases morbidity and increases life expectancy. Beta blockers are widely used in the treatment of hypertension. Beta blockers are effective only when they are rationally prescribed and used. It is retrospective type of study during which data of 50 hypertensive patients with primary hypertension using beta blockers were collected to analyze whether beta blockers are rationally prescribed and used. After therapy with beta blockers Blood pressure is effectively controlled. After the therapy 20 % patient have B.P in range of 110-130, 56% patients have B.P in range of 120- 130 and 24% have B.P in range of 130-140.It is concluded that blood pressure is effectively controlled when beta blockers rationally used. It should be given with caution in older and diabetic patients because it increases the risk of stroke in older patients. It is most effective when given in combination. Key words; Beta blockers, Hypertension, rational use, INTRODUCTION: systolic hypertension, white coat hypertension Hypertension is defined as either a sustained and resistant hypertension. (5, 6) systolic blood pressure of greater than 140 Although exact causes of primary hypertension mmHg or sustained diastolic blood pressure of is not fully understood it is known that some greater than 90mmHg.
    [Show full text]
  • Selection of a Mineralocorticoid Receptor Antagonist for Patients with Hypertension Or Heart Failure
    European Journal of Heart Failure (2014) 16, 143–150 REVIEW doi:10.1111/ejhf.31 Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure Javaid Iqbal1*, Yasir Parviz1, Bertram Pitt2, John Newell-Price3, Abdallah Al-Mohammad1, and Faiez Zannad4 1Department of Cardiovascular Science at the University of Sheffield and Cardiology Department at Sheffield Teaching Hospitals NHS Trust, Sheffield,K; U 2Cardiovascular Centre, University of Michigan, Ann Arbor, MI, USA; 3Department of Human Metabolism at the University of Sheffield and Endocrinology Department at Sheffield Teaching Hospitals NHS Trust, Sheffield, UK; and 4INSERM, Centre d’Investigation Clinique and Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Université de Lorraine, Nancy, France Received 8 April 2013; revised 15July2013; accepted 19July2013; online publish-ahead-of-print 14 December 2013 Clinical trials have demonstrated morbidity and mortality benefits of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. These studies have used either spironolactone or eplerenone as the MRA. It is generally believed that these two agents have the same effects, and the data from studies using one drug could be extrapolated for the other. National and international guidelines do not generally discriminate between spironolactone and eplerenone, but strongly recommend using an MRA for patients with heart failure due to LV systolic dysfunction and post-infarct LV systolic dysfunction. There are no major clinical trials directly comparing the efficacy of these two drugs. This article aims to compare the pharmacokinetics and pharmacodynamics of spironolactone and eplerenone, and to analyse the available data for their cardiovascular indications and adverse effects.
    [Show full text]